4baseCare
Category: AI in Healthcare
A precision oncology startup developing AI-powered genomic tests and personalized diagnostic solutions specifically optimized for the Asian population. 4baseCare was founded in 2018. The company is led by Hitesh Goswami. Based in Bengaluru, India. Team size: 251-500. Total funding raised: ~$19M (₹158Cr+). Latest round: Series B (₩90Cr first close, Jan 2026). Key investors include ["Yali Capital","Mount Judi Ventures","growX ventures","Season Two Ventures","Infosys Innovation Fund","First In Ventures","Ashish Kacholia","Lashit Sanghvi"].
- Founded
- 2018
- Headquarters
- Bengaluru, India
- Team size
- 251-500
- Total funding
- ~$19M (₹158Cr+)
Value proposition
Provides affordable and population-specific genomic testing that identifies the most effective targeted therapies for cancer patients, bridging the gap between advanced genomics and clinical practice in underserved markets.
Products and solutions
["TarGT Panels: Comprehensive genomic profiling tests (tissue, liquid, SoLiQ dual-source).","SoLiQ: Dual-source genomics combining tissue, liquid, and germline for complete biomarker profiling.","OncoTwin: AI-powered clinical decision support platform with patient twin matching, MTB intelligence, and clinical trial optimization.","Global Cancer Diversity Atlas (GCDA): World's first atlas capturing cancer's genomic diversity across underrepresented populations.","HRD Testing (PARPredict): Scar-based HRD assay for PARP inhibitor therapy selection.","Germline Cancer Risk Testing: Hereditary variant detection for risk assessment and family care.","AI-Powered Oncology Labs: Advanced diagnostic facilities with NABL accreditation."]
Unique value
Unlike most global genomic databases which are Caucasian-centric, 4baseCare focuses on the 'Asian Genome,' developing proprietary panels that account for the unique genetic variations found in Asian populations.
Target customer
Oncologists, cancer hospitals and clinics, pharmaceutical companies, and cancer patients seeking personalized treatment plans.
Industries served
["Healthcare","Biotechnology","Oncology","Genomics","Digital Health"]
Technology advantage
Combines Next-Generation Sequencing (NGS) with proprietary AI algorithms to reduce the cost of precision medicine by up to 80% compared to international competitors, while maintaining high clinical accuracy.
How they differentiate
4baseCare differentiates by focusing specifically on the 'Asian Genome.' While most global genomic databases are 95% Caucasian-centric, 4baseCare has developed proprietary gene panels (TarGT) optimized for genetic variations unique to Asian populations. Additionally, they offer these tests at a price point approximately 70-80% lower than international competitors.
Main competitors
["MedGenome","Strand Life Sciences","Foundation Medicine","Guardant Health"]
Key partnerships
["Illumina Accelerator (Alumnus)","Leading oncology hospitals in India and South East Asia (e.g., Mount Elizabeth Singapore)","Pharmaceutical companies for Real-World Evidence (RWE) and clinical trial matching","Wipro (Strategic collaboration for genomic data solutions)","Owkin (Partnership for inclusive AI-driven cancer research, Feb 2026)","Caritas Hospitals (Partnership for personalised cancer care in Kerala, Feb 2026)","Maharashtra Govt (MoU for Centre of Excellence in precision oncology, Mar 2026)","Bio Valley Incubation Council & Define Bio (MoU for genomics ecosystem at AMTZ, Mar 2026)","Memorial Sloan Kettering Cancer Center (MSK iHub Challenge 2025 Cohort)"]
Notable customers
["Mount Elizabeth Hospital (Singapore)","AIIMS (Research Collaboration)","Tata Memorial Centre (Research Collaboration)","Wipro (Strategic Partner)","Caritas Hospitals (Kerala)","Apollo Hospitals","Pathfinder (Philippines Genomics Lab)"]
Major milestones
["Selected for the Illumina Accelerator in 2019 (the first Indian company to be selected).","Launched 'TarGT Indivu' - India's first population-specific tumor gene panel.","Closed $9.8M (Rs 90 Cr) first close of Series B round in Jan 2026 to expand AI-powered labs globally.","Launched Global Cancer Diversity Atlas (GCDA) and inaugurated Bangalore HQ by Mr. Narayana Murthy (May 2025).","Selected for MSK Innovation Hub Challenge 2025 Cohort at Memorial Sloan Kettering Cancer Center (Dec 2025).","Partnership with Owkin for inclusive AI-driven cancer research (Feb 2026).","MoU with Maharashtra Govt to establish Centre of Excellence for precision oncology (Mar 2026).","Bangalore Lab achieved NABL (ISO 15189) accreditation (Apr 2026)."]
Growth metrics
Tested over 23,000 genomic profiles mapped; 70+ cancer types with multidimensional data; 8+ countries represented; expanding across India, SE Asia, Middle East, Latin America, and Central Asia; 80% cost reduction in precision testing compared to global standards.
Market positioning
Specialized precision oncology challenger focusing on affordable, population-specific genomics for emerging markets.
Geographic focus
India, South East Asia (Singapore, Philippines, Thailand), and the Middle East.
Patents and IP
Proprietary 'TarGT' gene panels and specialized bioinformatics pipelines for Asian-specific mutation analysis (specific patent registration numbers not publicly disclosed).
About Hitesh Goswami
Hitesh Goswami is a biotech entrepreneur with over 20 years of experience in genomics and molecular diagnostics. Prior to founding 4baseCare, he co-founded Bionivid Technology, a leading genomics service provider in India. He has also held scientific and leadership roles at Genotypic Technology and Nicholas Piramal India Ltd, where he focused on pharma drug discovery and genome informatics. He is an alumnus of the Illumina Accelerator.
Official website: https://4basecare.com/